Incidence, risk factors, and outcome of antithymocyte globulin treatment of steroid-resistant rejection after liver transplantation.
We retrospectively analyzed the incidence and outcome of steroid-resistant rejection (SRR) during the first 6 months after OLT in 126 patients receiving triple immunosuppression. A total of 95 patients either did not experience acute rejection at all or had acute rejection that subsided without additional treatment. A total of 31 patients had biopsy-proven acute rejection that required therapy: 18 patients had acute rejection that responded to steroid therapy (steroid-sensitive rejection, SSR); the remaining 13 patients had SRR and received ATG. At the onset of acute rejection, no differences in clinical, biochemical, or immunological parameters were present between patients with SSR and SRR. However, the histological grade of acute rejection in the initial biopsy was higher in patients with SRR (P = 0.05). ATG treatment was effective in 10 of the 13 patients and was not associated with an increased incidence of opportunistic infections. Patient and graft survival rates at 2 years were comparable in the three groups. These data show that the incidence of SRR during the first 6 months after OLT is low, and that its treatment with ATG is both effective and well tolerated.
Bijleveld
C G
CG
Department of Internal Medicine, University Hospital, Groningen, The Netherlands.
Klompmaker
I J
IJ
van den Berg
A P
AP
Gouw
A S
AS
Hepkema
B G
BG
Haagsma
E B
EB
Verwer
R
R
Slooff
M J
MJ
D000328:Adult; D000368:Aged; D004351:Drug Resistance; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D013256:Steroids / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000276:immunology*; D016896:Treatment Outcome
D007136:Immunoglobulins; D013256:Steroids